npg

Original Article

Frequency of *CYP2C9* alleles in Koreans and their effects on losartan pharmacokinetics

Jung-woo BAE[1, 3, #], Chang-ik CHOI[1, #], Mi-jeong KIM[1], Da-hee OH[1], Seul-ki KEUM[1], Jung-in PARK[1], Bo-hye KIM[1], Hye-kyoung BANG[1], Sung-gon OH[1], Byung-sung KANG[1], Hye-in LEE[1], Yun-jeong LEE[1], Hyun-joo PARK[2], Hae-deun KIM[2], Ji-hey HA[2], Hee-jung SHIN[2], Young-hoon KIM[2], Han-sung NA[2], Myeon-woo CHUNG[2], Soon-young HAN[2], Seung-hee KIM[2], Choon-gon JANG[1], Seok-yong LEE[1, *]

[1]School of Pharmacy, Sungkyunkwan University, Suwon, 440–746, Korea; [2]National Institute of Food and Drug Safety Evaluation, KFDA, Cheongwon-gun, 363–951, Korea; [3]College of Pharmacy, Keimyung University, Daegu, 704–701, Korea

Aim: CYP2C9 enzyme metabolizes numerous clinically important drugs. The aim of this study is to investigate the frequencies of *CYP2C9* genotypes and the effects of selected alleles on losartan pharmacokinetics in a large sample of the Korean population.
Methods: The *CYP2C9* gene was genotyped in 1796 healthy Korean subjects. *CYP2C9* alleles (*CYP2C9*1, *2, *3*, and *13* alleles) were measured using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay and direct sequencing assay. The enzymatic activity of each *CYP2C9* genotype was evaluated using losartan as the substrate.
Results: The frequencies of *CYP2C9*1, *3*, and *13* allele were 0.952 (95% confidence interval 0.945–0.959), 0.044 (95% CI 0.037–0.051), and 0.005 (95% CI 0.003–0.007), respectively. The frequencies of the *CYP2C9*1/*1, *1/*3, *1/*13*, and *3/*3* genotypes were 0.904 (95% CI 0.890–0.918), 0.085 (95% CI 0.072–0.098), 0.009 (95% CI 0.005–0.013), and 0.001 (95% CI 0.000–0.002), respectively. In the pharmacokinetics studies, the $AUC_{0-\infty}$ of losartan in *CYP2C9*3/*3* subject was 1.42-fold larger than that in *CYP2C9*1/*1* subjects, and the $AUC_{0-\infty}$ of E-3174, a more active metabolite of losartan, in *CYP2C9*3/*3* subject was only 12% of that in *CYP2C9*1/*1* subjects.
Conclusion: The results confirmed the frequencies of *CYP2C9* genotypes in a large cohort of Koreans, and detected the *CYP2C9*3/*3* genotype. *CYP2C9*3/*3* subjects metabolized much less losartan into E-3174 than *CYP2C9*1/*1* subjects.

Keywords: CYP2C9; allele; genotype; Korean; pharmacokinetics; losartan

Introduction

The cytochrome P450 (CYP) 2C9 enzyme oxidizes many clinically important compounds, including drugs with narrow therapeutic indexes such as warfarin, tolbutamide, and phenytoin, as well as other common drugs such as glibenclamide, glimepiride, glipizide, losartan, irbesartan, torsemide, and many anti-inflammatory drugs[1, 2]. Genetic polymorphisms in enzymes that metabolize drugs are major determinants of variability in individual response. Thirty-five alleles of the *CYP2C9* gene have been reported (http://www.cypalleles.ki.se/cyp2c9.htm) and three of these, *CYP2C9*1, *2*, and *3*, are frequently identified in most populations. The *CYP2C9*2* allele is the most common deleterious allele among

people of European descent, with a frequency of 0.080 to 0.191. The *CYP2C9*3* allele is less common (0.033–0.162)[3]. In contrast, the *CYP2C9*2* allele is rare among East Asians[3, 4], and *CYP2C9*3* is more common than that in Europeans (0.007 to 0.060)[5]. In addition, *CYP2C9*3* homozygotes are seldom detected in East Asian populations[5]. *CYP2C9*3* has the lowest metabolic activity *in vitro*, while *CYP2C9*2* has an intermediate enzyme activity, and *CYP2C9*1* has the highest activity[6]. Individuals with mutant *CYP2C9* variants may not metabolize drugs adequately, leading to drug toxicity. Therefore, drug doses must be adjusted according to genotype. The frequencies of *CYP2C9* alleles vary between populations, information that is useful for clinical pharmacotherapy. The frequencies of *CYP2C9* alleles and genotypes in the Korean population have been calculated[5, 7–9], however, there are significant discrepancies in the reported *CYP2C9*3* frequencies. Thus, we measured the *CYP2C9* allele and genotype frequencies in a large Korean cohort, where we

detected the *CYP2C9*3/*3* genotype and analyzed the effects of the *CYP2C9*3/*3* genotype on losartan pharmacokinetics.

Materials and methods

Subjects
We enrolled 1796 unrelated healthy Korean volunteers in this genotyping study. Written informed consent was obtained from all volunteers.

Genotyping tests
Genomic DNA was isolated from peripheral blood leukocytes using the Wizard® Genomic DNA Kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Analyses of the *CYP2C9*2, *3*, and *13* alleles were performed using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP), as described previously[5]. The *CYP2C9*1* allele was assigned in the absence of other detectable alleles. The genotypes identified by PCR-RFLP were confirmed by sequence analysis. Exons and exon/intron junctions of the *CYP2C9* gene were amplified as described with slight modifications[5, 10]. The PCR products were purified using a PCR purification kit (AxyPrep® PCR Clean-up Kit, Axygen Bioscience Inc, Union City, CA, USA) and sequenced on an ABI3730 automatic sequencer (Applied Biosystems Inc, Foster City, CA, USA) using a BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems Inc, Delaware, USA).

Protocol for pharmacokinetic studies
Thirteen healthy male Korean subjects with *CYP2C9*1/*1* (*n*=12) or *CYP2C9*3/*3* (*n*=1) genotypes were selected for a pharmacokinetic study of losartan. Although two subjects with *CYP2C9*3/*3* were detected, one did not provide written informed consent. Thus, only one subject with *CYP2C9*3/*3* was enrolled in the pharmacokinetic study.

The subjects were between 20 and 26 years old and had body mass indexes between 21 and 25 kg/m². All subjects were healthy as defined by medical history, physical examination, and routine laboratory tests (blood chemistry, hematology, and urine analysis). The subjects were asked to refrain from ingesting medications, caffeine, grapefruit products, and alcoholic beverages and from smoking for at least 1 week before and during the study period. All subjects provided verbal and written informed consent after being given an explanation of the experimental procedures and purpose of the study. The institutional ethics committee of the School of Pharmacy, Sungkyunkwan University, Korea approved the study protocol. All procedures were performed in accordance with the recommendations of the Declaration of Helsinki on biomedical research involving human subjects.

On the day of the study, each subject received 50 mg of losartan potassium (Cozaar®, MSD-Korea, Seoul, Korea) orally with 240 mL of water after an overnight fast. The subjects maintained the fasting state for 4 h after receiving the drug. Before and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 h, venous blood samples (10 mL) were collected in heparinized tubes and centrifuged for 10 min at 3000 r/min. The plasma was separated and stored at -70 °C until needed.

Assay of losartan and E-3174 in plasma
CYP2C9 metabolizes losartan to a more active metabolite, E-3174[11]. Thus, the losartan and E-3174 concentrations in the plasma were determined by HPLC with a fluorescence detector as previously reported with modifications[12]. Briefly, 1.0 mL of plasma, 150 ng of valsartan (IS), and 200 μL of 1 mol/L phosphoric acid were mixed in a glass tube, and extracted with 7 mL of methyl *tert*-butyl ether (MTBE) with constant vigorous stirring for 1 min. After centrifuging (2500 r/min for 10 min), the organic layer was transferred to another tube with 200 μL of 0.05 mol/L sodium hydroxide and stirred vigorously for 1 min. The samples were again centrifuged at 2500 r/min for 10 min. The aqueous layer was collected, and residual MTBE was removed by nitrogen evaporation. The sodium hydroxide layer was acidified with 50 μL of 0.2 mol/L phosphoric acid and mixed. The aqueous fraction was washed by adding 6 mL of *n*-hexane and mixing for 1 min. After centrifuging, the hexane was discarded, and residual *n*-hexane was removed by nitrogen evaporation. Methanol (150 μL) was added to 250 μL of the re-extracted water phase, and 100 μL of the resulting mixture was injected into the HPLC system. The HPLC system consisted of a Waters Model 515 HPLC pump, a Waters Model 717 Plus autosampler, a Waters 474 scanning fluorescence detector, and column oven (Waters, Milford, MA, USA). Separations were performed on a 5 μm Luna CN column (4.5 mm×250 mm; Phenomenex, Torrance, CA, USA). The mobile phase was 15 mmol/L phosphoric acid/acetonitrile (65:35, *v/v*) adjusted to pH 3.0 with 5 mol/L sodium hydroxide at 1 mL/min. The effluents were detected by fluorescence with excitation at 250 nm and emission at 380 nm. The standard curves for losartan and E-3174 were linear from 5 to 1000 ng/mL (r^2 >0.999). The mean accuracy for losartan and E-3174 were 90%–102% and 96%–101%, respectively. The coefficients of variation (within-day and between-day precisions) of losartan and E-3174 were <9% and 10%, respectively.

Pharmacokinetic analysis
The pharmacokinetic parameters of losartan and E-3174 were calculated by non-compartmental methods from the blood sampling times, maximum plasma concentration (C_{max}), and time to reach C_{max} (t_{max}) using the BA Calc 2007 analysis program (KFDA, Seoul, Korea). The area under the curve (AUC) for plasma concentration-time was calculated using the linear trapezoidal rule. The elimination rate constant (k_e) was determined by linear regression analysis of the log-linear portion of the plasma concentration-time curve. The AUC from 0 to infinity ($AUC_{0-\infty}$) was calculated as $AUC_{0-\infty}=AUC+C_t/k_e$ (C_t being the final plasma concentration). The half-life ($t_{1/2}$) was calculated as $t_{1/2}=\ln 2/k_e$. The apparent oral clearance (CL/F) of losartan was calculated as $CL/F=Dose/AUC_{0-\infty}$.

Statistical analysis
Data were compiled according to the genotype and allele frequencies. The frequencies of each allele are reported with

95% confidence intervals. Hardy-Weinberg equilibrium was evaluated by comparing the genotype frequencies with the expected values using a contingency table χ^2 test. Statistical significance was determined by χ^2 test; a *P*-value less than 0.05 was considered significant. The pharmacokinetic data are expressed as mean±SD.

Results

Frequencies of *CYP2C9* alleles and genotypes

The estimated frequencies of the *CYP2C9* alleles and genotypes in the Korean population are summarized in Table 1. The genotype frequency distribution did not deviate significantly from Hardy-Weinberg equilibrium. *CYP2C9*1* was the most common allele (0.952, 95% CI: 0.945–0.959). The most common variant allele was *CYP2C9*3* (0.044, 95% CI: 0.037–0.051). The *CYP2C9*1/*3* frequency in this study was more than four times higher than previously reported[7] (*P*<0.01, Table 2). The *CYP2C9*13* frequency in our sample was 0.005 (95% CI: 0.003–0.007). There were 1624 subjects with the *CYP2C9*1/*1* genotype (0.904, 95% CI: 0.890–0.918), 153 with the *CYP2C9*1/*3* genotype (0.085, 95% CI: 0.072–0.098), 17 with the *CYP2C9*1/*13* genotype (0.009, 95% CI: 0.005–0.013), and 2 with the *CYP2C9*3/*3* genotype (0.001, 95% CI: 0.000–0.002) (Table 1). The genotype results from PCR-RFLP corresponded with the sequencing results (data not shown).

Table 1. *CYP2C9* allele (A) and genotype (B) frequencies in a large Korean sample. The expected genotype frequencies were calculated from the allele frequencies using the Hardy-Weinberg equation.

A

Allele	*n* (3592)	Frequency	95% CI
*CYP2C9*1*	3418	0.952	0.945–0.959
*CYP2C9*2*	0	0.000	0.000–0.000
*CYP2C9*3*	157	0.044	0.037–0.051
*CYP2C9*13*	17	0.005	0.003–0.007

B

Genotype	Number of subjects	Observed frequency	95% CI	Expected frequency
*CYP2C9*1/*1*	1624	0.904	0.890–0.918	0.905
*CYP2C9*1/*3*	153	0.085	0.072–0.098	0.083
*CYP2C9*1/*13*	17	0.009	0.005–0.013	0.009
*CYP2C9*3/*3*	2	0.001	0.000–0.002	0.002
*CYP2C9*3/*13*	0	0.000	0.000–0.000	0.000
*CYP2C9*13/*13*	0	0.000	0.000–0.000	0.000

The *CYP2C9*3* allele frequency in our Korean sample was slightly (although not significantly) higher than in Chinese samples, and was significantly higher than in Japanese samples (*P*<0.01) (Table 3). The *CYP2C9*13* allele frequency in our sample was slightly lower than in Chinese samples,

and slightly higher than in Japanese samples, although these differences were not significant (Table 3).

Pharmacokinetics of losartan

The losartan and E-3174 pharmacokinetic parameters were measured in one subject with the *CYP2C9*3/*3* genotype, a rare genotype in Koreans (0.1%, Table 1). In this subject, the C_{max} and $AUC_{0-\infty}$ of losartan were slightly higher and the CL/F was lower than in *CYP2C9*1/*1* subjects, but losartan metabolism to E-3174 was almost completely blocked (Figure 1, Table 4).


Figure 1. Plasma concentration-time profiles of losartan (A) and E-3174 (B) in subjects with the *CYP2C9*1/*1* (*n*=12, open circles) or *CYP2C9*3/*3* (*n*=1, closed circles) genotypes after administration of a single 50 mg oral dose of losartan.

Discussion

CYP2C9 catalyzes phase I metabolism for approximately 15%–20% of the drugs subject to this reaction. The CYP2C9 allelic variants *CYP2C9*2*, *CYP2C9*3*, and *CYP2C9*13* code for enzymes with approximately 10%–40%, 5%–15%, and 1%–12% of the activity of *CYP2C9*1*, respectively[4, 10, 29]. The *CYP2C9*2* allele is the most common variant allele among people of European descent with a frequency of approximately 0.132[4, 9, 16, 30]. In contrast, the *CYP2C9*2* allele is rare in East Asians[3] (Table 3). To date, the *CYP2C9*2* allele has been detected in only two East Asian subjects, both Chinese with the *CYP2C9*1/*2* genotype[9, 16]. We did not detect the *CYP2C9*2* allele in our sample of 2154 Koreans (Table 3).

Functionally, the *CYP2C9*3* allele has the lowest metabolic activity *in vitro*, while *CYP2C9*2* lies between *CYP2C9*3* and *CYP2C9*1*[6]. Europeans have significant heterogeneity in

Table 2. Comparisons of reported *CYP2C9* allele frequencies in Koreans.

| n | CYP2C9 allele frequency | | | | Reference |
	*1	*2	*3	*13	
3592	0.952 (0.945–0.959)	0.000 (0.000–0.000)	0.044 (0.037–0.051)	0.005 (0.003–0.007)	Present study
716	0.934 (0.916–0.952)	0.000 (0.000–0.000)	0.060 (0.043–0.077)	0.006 (0.000–0.012)	[5]
1148	0.989 (0.983–0.995)	0.000 (0.000–0.000)	0.011[c] (0.005–0.017)	ND	[7]
590	0.947 (0.929–0.965)	0.000 (0.000–0.000)	0.051 (0.033–0.069)	0.002 (0.000–0.006)	[13]

Values in parentheses represent 95% confidence intervals; *n*=number of alleles; differences between frequency data were calculated using the chi-square test. ND=Not determined. [c]*P*<0.01 between present and previous studies [7] (95% CI on the difference 0.024–0.042).

Table 3. *CYP2C9* allele frequencies in East Asian populations.

| Populations | n | CYP2C9 allele frequency | | | | Reference |
		*1	*2	*3	*13	
Korean	4308	0.949 (0.942–0.956)	0.000 (0.000–0.000)	0.046 (0.040–0.052)	0.005 (0.003–0.007)	Present study[#]
Chinese	2174	0.964	0.000	0.036	ND	[14]
	1008	0.967	0.000	0.033	ND	[15]
	788	0.963	0.001	0.036	ND	[16]
	400	0.975	0.000	0.025	ND	[8]
	338	0.967	0.000	0.033	ND	[17]
	230	0.983	0.000	0.017	ND	[18]
	204	0.951	0.000	0.049	ND	[19]
	796	0.958	0.001	0.041	ND	[9]
	658	-	-	-	0.006	[20]
	294	-	-	-	0.010	[21]
Sum of Chinese	5938 (952)[*]	0.964 (0.959–0.969)	0.003 (0.002–0.004)	0.035 (0.030–0.040)	0.007 (0.003–0.011)	
Japanese	1000	0.966	0.000	0.034	ND	[9]
	1448	0.968	0.000	0.032	ND	[22]
	1200	0.979	0.000	0.021	ND	[23]
	524	0.968	0.000	0.031	0.002	[10]
	436	0.979	0.000	0.021	ND	[24]
	400	0.965	0.000	0.035	ND	[8]
	280	0.982	0.000	0.018	ND	[25]
	236	0.970	0.000	0.030	ND	[26]
	246	0.955	0.000	0.045	ND	[27]
	294	0.993	0.000	0.007	ND	[28]
Sum of Japanese	6064 (524)[&]	0.972 (0.968–0.976)	0.000 (0.000–0.000)	0.028[c] (0.024–0.032)	0.002 (0.000–0.005)	

Values in parentheses represent 95% confidence intervals; *n*=number of alleles; differences between frequency data were calculated using the chi-square test. ND=Not determined.

#, Data were combined with a previous study[5].

*, &, Values in parentheses represent the total numbers with the *CYP2C9*13* allele.

[c]*P*<0.01 between present study and sum of Japanese (95% CI on the difference 0.010–0.026).

the *CYP2C9*2* allele frequency (ranging from 0.033 to 0.162), whereas the *CYP2C9*3* allele is less common[6]. The *CYP2C9*3* frequency in Koreans was previously reported as 0.011[7], but we previously found it to be 0.060[5]. Because these results are so different, an additional study was needed. In addition, the first study found no difference in the *CYP2C9*3* frequency between Korean and Japanese samples, but our previous report did[5]. In Korean population (2154 unrelated subjects), the *CYP2C9*3* frequency was 0.046, significantly higher

(*P*<0.001) than the mean frequency in Japanese (0.028), but similar to the frequency in Chinese (0.035) (Table 3). Because the *CYP2C9* allele and genotype frequencies vary among studies, a large sample, such as ours, should reflect actual genotype frequencies. A recent study of 295 Koreans reported a *CYP2C9*3* frequency similar to the one found in this study[13], but the *CYP2C9*13* frequency was lower. The *CYP2C9*13* frequency in our study was 2.5-fold higher. Because the number of samples in this study (*n*=3592) was much higher

Table 4. Pharmacokinetic parameters of oral losartan in subjects with the CYP2C9*1/*1 and CYP2C9*3/*3 genotypes. Mean±SD.

Variable	CYP2C9*1/*1 (n=12)	CYP2C9*3/*3 (n=1)
Losartan		
C_{max} (ng/mL)	235.1±98.4 (172.6, 297.6)	440.2
$t_{1/2}$ (h)	1.92±0.76 (1.44, 2.40)	4.72
CL/F (L/h)	0.094±0.018 (0.082, 0.106)	0.037
$AUC_{0-\infty}$ (ng·h/mL)	552.2±102.2 (487.3, 617.1)	1334.9
E-3174		
C_{max} (ng/mL)	524.3±84.1 (470.8, 577.8)	19.1
$t_{1/2}$ (h)	4.29±0.40 (4.04, 4.54)	10.56
$AUC_{0-\infty}$ (ng·h/mL)	3471.9±466.2 (3175.7, 3768.1)	400.9

Values in parentheses represent 95% confidence intervals. C_{max}, maximum plasma concentration; $AUC_{0-\infty}$, area under the plasma concentration-time curve from time 0 to infinity; $t_{1/2}$, elimination half-life; CL/F, apparent oral clearance; n, number of subjects.

than that in other study (n=590)[13], this study may serve more reliable information on the frequencies of CYP2C9 alleles in Korean population.

The CYP2C9*13 allele was first identified in a Chinese sample, and the CYP2C9*3/*13 genotype confers a remarkable reduction in metabolic activity[21]. In this study, 17 of 1796 subjects had the CYP2C9*1/*13 genotype, while CYP2C9*13/*13 and *3/*13 were not found (Table 1). The CYP2C9*13 variant has impaired activity towards a number of substrates in vivo[20, 29, 31], and has only been found in East Asians (Table 3). It is apparently absent from African-American, European, Hispanic, and Ashkenazi Jewish populations[32].

In this study, two subjects were homozygous for CYP2C9*3/*3, but one did not provide written informed consent for inclusion in the pharmacokinetic study. We evaluated the enzymatic activity of the remaining CYP2C9*3/*3 homozygote using losartan. In the CYP2C9*3/*3 subject, the C_{max} (187% of CYP2C9*1/*1) and AUC (242% of CYP2C9*1/*1) of losartan increased and the C_{max} (3.6% of CYP2C9*1/*1) and AUC (11.5% of CYP2C9*1/*1) of E-3174 decreased compared with CYP2C9*1/*1 subjects. In the CYP2C9*3/*3 subject, E-3174 formation from losartan decreased markedly compared to CYP2C9*1/*1 subjects, therefore the $AUC_{0-\infty}$ was about 1/9th that of CYP2C9*1/*1 subjects. These results agree with a previous report from Sweden[33]. Although both losartan and E-3174 block angiotensin II receptors, E-3174 is at least 10-fold more potent than losartan[34], and the clinical effects of losartan are mainly due to E-3174. Thus, losartan may have reduced antihypertensive effects in CYP2C9*3/*3 subjects than in CYP2C9*1/*1 subjects. Therefore, CYP2C9*3/*3 patients with hypertension might do well to take other hypertensive agents that are not metabolized by CYP2C9. In previous studies, losartan conversion to E-3174 was significantly reduced in the CYP2C9*1/*3 (50%–95% of that in CYP2C9*1/*1)[20, 33, 35, 36] and *1/*13 genotypes (62% of that in CYP2C9*1/*1)[20]. Because the $AUC_{0-\infty}$ of E-3174 did not differ significantly between

CYP2C9*1/*1 subjects and CYP2C9*3 or *13 heterozygotes, these genotypes did not affect the clinical effects of losartan. Because the CYP2C9*3/*3 genotype has almost no enzyme activity, the use of warfarin, phenytoin, and oral hypoglycemic agents might be hazardous[1, 2, 6].

In summary, the CYP2C9*3 frequency in the Korean population was estimated to be 0.044 (95% CI 0.037–0.051) and the CYP2C9*13 frequency was estimated to be 0.005 (95% CI 0.003–0.007). Only four genotypes (CYP2C9*1/*1, *1/*3, *1/*13, and *3/*3) were found in a large Korean sample. CYP2C9*3/*3 subjects formed markedly less E-3174 from losartan than CYP2C9*1/*1 subjects, suggesting a profound reduction in antihypertensive effect of losartan in this genotype.

Author contribution
Jung-woo BAE performed genotyping and PK study and wrote the paper. Chang-ik CHOI performed genotyping and PK study and wrote the paper. Mi-jeong KIM performed volunteer recruiting and genotyping. Da-hee OH performed genotyping and PK study. Seul-ki KEUM performed genotyping and PK study. Jung-in PARK performed volunteer recruiting and genotyping. Bo-hye KIM performed genotyping and PK study. Hye-kyoung BANG performed volunteer recruiting and genotyping. Sung-gon OH performed genotyping and PK study. Byung-sung KANG performed volunteer recruiting and genotyping. Hye-in LEE determined losartan concentration in plasma. Yun-jeong LEE performed volunteer recruiting and genotyping. Hyun-joo PARK performed volunteer recruiting and genotyping. Hae-deun KIM performed volunteer recruiting and genotyping. Ji-hey HA performed volunteer recruiting and genotyping. Hee-jung SHIN performed volunteer recruiting and genotyping. Young-hoon KIM performed volunteer recruiting and genotyping. Han-sung NA performed volunteer recruiting and genotyping. Myeon-woo CHUNG performed volunteer recruiting and genotyping. Soon-young HAN determined losartan concentration in plasma. Seung-hee KIM determined losartan concentration in plasma. Choon-gon JANG analyzed data. Seok-yong LEE designed research and wrote the paper.

References
1. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525–38.
2. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003; 33: 23–30.
3. García-Martín E, Martínez C, Ladero JM, Agúndez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006; 10: 29–40.
4. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004; 50: 195–200.

5   Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, *et al*. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005; 60: 418–22.

6   Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the *in-vivo* and human data. Pharmacogenetics 2002; 12: 251–63.

7   Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, *et al*. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 277–80.

8   Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, *et al*. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008; 84: 347–61.

9   Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, *et al*. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 2010; 50: 929–40.

10 Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, *et al*. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006; 16: 497–514.

11 Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23: 207–15.

12 Ritter MA, Furtek CI, Lo MW. An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 1997; 15: 1021–9.

13 Lee HW, Lim MS, Lee J, Jegal MY, Kim DW, Lee WK, *et al*. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. J Clin Pharm Ther 2011. doi: 10.1111/j.1365-2710.2010.01238.x.

14 Hong X, Zhang S, Mao G, Jiang S, Zhang Y, Yu Y, *et al*. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 2005; 61: 627–34.

15 Yu BN, Luo CH, Wang D, Wang A, Li Z, Zhang W, *et al*. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 2004; 348: 57–61.

16 Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Xu CD, *et al*. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fund Clin Pharmacol 2003; 17: 373–6.

17 Chen K, Wang R, Wen SY, Li J, Wang SQ. Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide. J Clin Pharm Ther 2005; 30: 241–9.

18 Wang SL, Huang J, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37–42.

19 Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P-4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 2001; 79: 841–7.

20 Li Z, Wang G, Wang LS, Zhang W, Tan ZR, Fan L, *et al*. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica 2009; 39: 788–93.

21 Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14: 465–9.

22 Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K, *et al*. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008; 31: 1549–57.

23 Yoshizawa M, Hayashi H, Tashiro Y, Sakawa S, Moriwaki H, Akimoto T, *et al*. Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thromb Res 2009; 124: 161–6.

24 Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7: 405–9.

25 Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P-450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monitor 1998; 20: 243–7.

26 Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, *et al*. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 2006; 80: 169–78.

27 Xie HG, Prasad H, Landau R, Kim RB, Cai WM, Ieiri I, *et al*. Frequency of the defective CYP2C9 variant alleles in different ethinc groups [abstract]. Clin Pharmacol Ther 2002; 71: P102.

28 Nakai K, Habano W, Nakai K, Fukushima N, Suwabe A, Moriya S, *et al*. Ethnic differences in *CYP2C9*2* (Arg144Cys) and *CYP2C9*3* (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci 2005; 78: 107–11.

29 Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, *et al*. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005; 33: 749–53.

30 Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628–31.

31 Bae JW, Choi CI, Jang CG, Lee SY. Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 2011; 71: 550–5.

32 Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11: 781–91.

33 Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, *et al*. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71: 89–98.

34 Sachinidis A, Ko Y, Weisser P, Meyer zu Brickwedde MK, Düsing R, Christian R, *et al*. EXP3174, a metabolite of losartan [MK 954, DuP 753] is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertens 1993; 11: 155–62.

35 Sekino K, Kubota T, Okada Y, Yamada Y, Yamamoto K, Horiuchi R, *et al*. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59: 589–92.

36 Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy 2003; 23: 720–5.